HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Olema Pharmaceuticals (NASDAQ:OLMA) and raises the price target from $25 to $28.

May 09, 2024 | 7:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Olema Pharmaceuticals and increases the price target from $25 to $28.
The increase in price target by HC Wainwright & Co. reflects a positive outlook on Olema Pharmaceuticals, likely due to strong performance or positive future expectations. This endorsement from a reputable analyst could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100